A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer. |
| |
| Authors: | R. V. Iaffaioli A. Tortoriello G. Facchini M. Santangelo G. De Sena G. Gesue L. Bucci G. Scaramellino E. Anastasio A. Finizio et al. |
| |
| Affiliation: | Istituto di Medicina Interna, Università di Cagliari, Italy. |
| |
| Abstract: | ![]()
Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation. |
| |
| Keywords: | |
|
